FDA approves new treatment for bladder cancer
On May 18, the U.S. the Food and Drug Administration (FDA) approved Tecentriq (atezolizumab) to treat urothelial carcinoma. Read more
RECENT POSTS
- Caring for diverse patient populations in their homes June 29, 2022
- Magnet® and COVID-19 response June 26, 2022
- Operationalizing the Pathway to Excellence® quality standard June 26, 2022
- ANA Statement on overturn of Roe vs. Wade June 24, 2022
- Do Vitamins, Plants Help Uterine Fibroid Risk or Treatment? June 23, 2022